Skip to main content

Table 3 Univariate and multivariate Cox regression analysis of factors associated with overall survival (OS) and disease-free survival (DFS)

From: Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Clinical variable Overall survival Disease free survival
  Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
  Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age(years) 0.632 (0.318-1.255) 0.190    0.547 (0.276-1.085) 0.084   
≥40 (n = 27, 37.5%)         
<40 (n = 45, 62.5%)         
Tumor homology 1.717 (0.846-3.485) 0.135    1.681 (0.832-3.396) 0.148   
Mixed (n = 22, 30.6%)         
Pure (n = 50, 69.4%)         
FIGO stage 3.883 (1.936-7.790) <0.001 3.478 (1.493-9.664) 0.004 3.572 (1.780-7.164) <0.001 3.104 (1.377-7.978) 0.007
IIa–IV (n = 26, 36.1%)         
Ia–Ib2 (n = 46, 63.9%)         
Tumor size 2.057 (1.022-4.141) 0.043    2.320 (1.148-4.688) 0.019   
>4 cm (n = 27, 37.5%)         
≤4 cm (n = 45, 62.5%)         
lymphatic metastasis 3.235 (1.642-8.139) 0.009 3.617 (1.441-11.326) 0.006 4.237 (1.792-6.524) 0.005 4.852 (1.613-8.794) 0.014
Positive (n = 42, 58.3%)         
Negative (n = 30, 41.7%)         
Vascular space invasion 1.923 (0.967-3.824) 0.062    1.529 (0.764-3.059) 0.231   
Positive (n = 33, 45.8%)         
Negative (n = 39, 54.2%)         
Depth of stromal invasion 2.039 (0.908-4.577) 0.084    2.480 (0.1.107-5.559) 0.027   
>2/3 (n = 33, 45.8%)         
≤2/3 (n = 28, 38.9%)         
Chemotherapy 0.227 (0.099-0.524) 0.001 0.264 (0.099-0.671) 0.003 0.223 (0.101-0.496) <0.001 0.221 (0.091-0.603) 0.006
EP or TP (n = 36, 50.0%)         
Others (n = 36, 50.0%)         
  1. FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval; EP, etoposide + cisplatin; TP, paelitaxel + cisplatin; Bold indicates significant values.